Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 6/2008

01-06-2008 | Review Article

Tolerability of Selective Serotonin Reuptake Inhibitors

Issues Relevant to the Elderly

Authors: Dr Brian Draper, Karen Berman

Published in: Drugs & Aging | Issue 6/2008

Login to get access

Abstract

Selective serotonin reuptake inhibitors (SSRIs) continue to be the first-choice antidepressant treatment for the elderly as they have similar efficacy to other antidepressants but better tolerability. However, recent concerns have emerged regarding a range of adverse effects that are more likely to occur in the elderly. In part this relates to the increased risk of drug interactions. Platelet dysfunction induced by SSRIs with high serotenergic activity is associated with gastrointestinal bleeding in the first month of treatment, although the overall evidence is weak. The risk of falls and fractures in elderly patients taking SSRIs is similar to that reported with use of tricyclic antidepressants. Hyponatraemia due to induction of the syndrome of inappropriate antidiuretic hormone secretion may be life threatening in the elderly but in most cases is asymptomatic and reversible. Extrapyramidal disorders such as parkinsonism and dyskinesias are more common in the elderly but are rare. There is a very low risk of cerebrovascular adverse reactions in patients taking SSRIs. There are inconsistent findings linking SSRIs with suicidal behaviour in late life and with the risk of cancer. Most of the newly identified adverse effects are either relatively uncommon or of debatable significance. Few differences have been identified among the SSRIs that are of clinical significance. However, it is recommended in the elderly that SSRIs should be titrated slowly to recommended therapeutic doses and used cautiously with other agents known to have the potential for drug interactions.
Literature
1.
Montgomery SA. Late-life depression: rationalizing pharmacological treatment options. Gerontology 2002 Nov–Dec; 48(6): 392–400PubMedCrossRef
2.
Alexopoulos GS, Schultz SK, Lebowitz BD. Late-life depression: a model for medical classification. Biol Psychiatry 2005 Aug 15; 58(4): 283–9PubMedCrossRef
3.
Faculty of Psychiatry of Old Age NSW Branch, RANZCP. Consensus guidelines for assessment and management of depression in the elderly. North Sydney (NSW): NSW Department of Health, 2001
4.
Unutzer J, Katon W, Callahan CM, et al. Depression treatment in a sample of 1,801 depressed older adults in primary care. J Am Geriatr Soc 2003 Apr; 51(4): 505–14PubMedCrossRef
5.
Skerritt U, Evans R, Montgomery SA. Selective serotonin reuptake inhibitors in older patients: a tolerability perspective. Drugs Aging 1997 Mar; 10(3): 209–18PubMedCrossRef
6.
Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005 Jan 5; 97(1): 30–9PubMedCrossRef
7.
Schuurmans J, Comijs H, Emmelkamp PM, et al. A randomized, controlled trial of the effectiveness of cognitive-behavioral therapy and sertraline versus a waitlist control group for anxiety disorders in older adults. Am J Geriatr Psychiatry 2006 Mar; 14(3): 255–63PubMedCrossRef
8.
Pollock B, Mulsant B, Rosen J, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 2002; 159(3): 460–5PubMedCrossRef
9.
10.
Wijkstra J, Lijmer J, Balk FJ, et al. Pharmacological treatment for unipolar psychotic depression: systematic review and meta-analysis. Br J Psychiatry 2006 May; 188: 410–5PubMedCrossRef
11.
Naranjo CA, Herrmann N, Mittmann N, et al. Recent advances in geriatric psychopharmacology. Drugs Aging 1995 Sep; 7(3): 184–202PubMedCrossRef
12.
Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997; 32Suppl. 1: 1–21PubMedCrossRef
13.
14.
Carrasco J, Sandner C. Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview. Int J Clin Pract 2005; 59: 1428–34PubMedCrossRef
15.
Corruble E, Guelfi J. Does increasing dose improve efficacy in patients with poor antidepressant response? A review. Acta Psychiatr Scand 2000; 101: 343–8PubMedCrossRef
16.
Nieuwstraten C, Labiris NR, Holbrook A. Systematic overview of drug interactions with antidepressant medications. Can J Psychiatry 2006 Apr; 51(5): 300–16PubMed
17.
Mitchell PB. Drug interactions of clinical significance with selective serotonin reuptake inhibitors. Drug Saf 1997 Dec; 17(6): 390–406PubMedCrossRef
18.
Sternbach H. Danger of MAOI therapy after fluoxetine withdrawal. Lancet 1988 Oct 8; II(8615): 850–1CrossRef
19.
Richards JB, Papaioannou A, Adachi JD, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 2007 Jan 22; 167(2): 188–94PubMedCrossRef
20.
Wessinger S, Kaplan M, Choi L, et al. Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal haemorrhage: a multicentre retrospective analysis. Aliment Pharmacol Ther 2006 Apr 1; 23(7): 937–44PubMedCrossRef
21.
de Abajo FJ, Rodriguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ 1999 Oct 23; 319(7217): 1106–9PubMedCrossRef
22.
Dalton SO, Johansen C, Mellemkjaer L, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med 2003 Jan 13; 163(1): 59–64PubMedCrossRef
23.
Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 1996 Oct; 57(10): 449–54PubMedCrossRef
24.
Hedenmalm K, Guzey C, Dahl M-L, et al. Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms. J Clin Psychopharmacol 2006 Apr; 26(2): 192–7PubMedCrossRef
25.
Laugesen S, Enggaard TP, Pedersen RS, et al. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Clin Pharmacol Ther 2005 Apr; 77(4): 312–23PubMedCrossRef
26.
Gillman P. A review of serotonin toxicity data: implications for the mechanism of antidepressant drug action. Biol Psychiatry 2006; 59: 1046–51PubMedCrossRef
27.
28.
Mottram P, Wilson K, Strobl J. Antidepressants for depressed elderly. Cochrane Database Syst Rev 2006; (1): CD003491
29.
Parker G. Differential effectiveness of newer and older antidepressants appears mediated by an age effect on the phenotypic expression of depression. Acta Psychiatr Scand 2002 Sep; 106(3): 168–70PubMedCrossRef
30.
McManus P, Mant A, Mitchell P, et al. Length of therapy with selective serotonin reuptake inhibitors and tricyclic antidepressants in Australia. Aust N Z J Psychiatry 2004 Jun; 38(6): 450–4PubMedCrossRef
31.
Wilson K, Mottram P. A comparison of side effects of selective serotonin reuptake inhibitors and tricyclic antidepressants in older depressed patients: a meta-analysis. Int J Geriatr Psychiatry 2004 Aug; 19(8): 754–62PubMedCrossRef
32.
Wee R. Review: tricyclic related drugs but not classical tricyclics, are a tolerable alternative to SSRIs in older people with depression. Evid Based Ment Health 2005; 8: 22PubMedCrossRef
33.
Bull SA, Hu XH, Hunkeler EM, et al. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA 2002 Sep 18; 288(11): 1403–9PubMedCrossRef
34.
Hu XH, Bull SA, Hunkeler EM, et al. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry 2004 Jul; 65(7): 959–65PubMedCrossRef
35.
Gandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care. N Engl J Med 2003 Apr 17; 348(16): 1556–64PubMedCrossRef
36.
Mullins CD, Shaya FT, Meng F, et al. Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram. Pharmacotherapy 2005 May; 25(5): 660–7PubMedCrossRef
37.
Macdonald L. Discontinuation reactions associated with SSRIs. Can Adv Drug React Newsl 1998; 8(4): 3–6
38.
Stahl M, Lindquist M, Pettersson M, et al. Withdrawal reactions with selective serotonin reuptake inhibitors as reported to the WHO system. Eur J Clin Pharmacol 1997; 53: 163–9PubMedCrossRef
39.
van Geffen ECG, Hugtenburg JG, Heerdink ER, et al. Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation. Eur J Clin Pharmacol 2005 Jun; 61(4): 303–7PubMedCrossRef
40.
Kyle CJ, Petersen HE, Overo KF. Comparison of the tolerability and efficacy of citalopram and amitriptyline in elderly depressed patients treated in general practice. Depress Anxiety 1998; 8(4): 147–53PubMedCrossRef
41.
Leonard BE. Pharmacological differences of serotonin reuptake inhibitors and possible clinical relevance. Drugs 1992; 43Suppl. 2: 3–9; discussion 9–10PubMedCrossRef
42.
Gravem A, Amthor KF, Astrup C, et al. A double-blind comparison of citalopram (Lu 10-171) and amitriptyline in depressed patients. Acta Psychiatr Scand 1987 May; 75(5): 478–86PubMedCrossRef
43.
Aberg-Wistedt A. The antidepressant effects of 5-HT uptake inhibitors. Br J Psychiatry Suppl 1989 Dec; (8): 32–40
44.
McManis P, Talley N. Nausea and vomiting associated with SSRIs. CNS Drugs 1997 Nov; 8(5): 394–401CrossRef
45.
Patel R. Clinical comparison of SSRIs in the treatment of geriatric depression: a review of the literature. Rev Clin Gerontol 2000 Nov; 10(4): 349–73CrossRef
46.
Bergeron R, Blier P. Cisapride for the treatment of nausea produced by selective serotonin reuptake inhibitors. Am J Psychiatry 1994 Jul; 151(7): 1084–6PubMed
47.
Rush AJ, Bose A. Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting. Depress Anxiety 2005; 21(1): 26–32PubMedCrossRef
48.
Meijer WEE, Heerdink ER, van Eijk JT, et al. Adverse events in users of sertraline: results from an observational study in psychiatric practice in the Netherlands. Pharmacoepidemiol Drug Saf 2002 Dec; 11(8): 655–62PubMedCrossRef
49.
Goldstein D, Hamilton S, Masica D, et al. Fluoxetine in medically stable, depressed geriatric patients: effect on weight. J Clin Psychopharmacol 1997 Oct; 17(5): 365–9PubMedCrossRef
50.
Rigler SK, Webb MJ, Redford L, et al. Weight outcomes among antidepressant users in nursing facilities. J Am Geriatr Soc 2001 Jan; 49(1): 49–55PubMedCrossRef
51.
Brymer C, Winograd CH. Fluoxetine in elderly patients: is there cause for concern? J Am Geriatr Soc 1992 Sep; 40(9): 902–5PubMed
52.
Lake MB, Birmaher B, Wassick S, et al. Bleeding and selective serotonin reuptake inhibitors in childhood and adolescence. J Child Adolesc Psychopharmacol 2000; 10(1): 35–8PubMedCrossRef
53.
Hergovich N, Aigner M, Eichler HG, et al. Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin Pharmacol Ther 2000 Oct; 68(4): 435–42PubMedCrossRef
54.
Layton D, Clark DW, Pearce GL, et al. Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England. Eur J Clin Pharmacol 2001 May; 57(2): 167–76PubMedCrossRef
55.
van Walraven C, Mamdani MM, Wells PS, et al. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ 2001 Sep 22; 323(7314): 655–8PubMedCrossRef
56.
Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001 Sep 1; 50(5): 345–50PubMedCrossRef
57.
Tata LJ, Fortun PJ, Hubbard RB, et al. Does concurrent prescription of selective serotonin reuptake inhibitors and nonsteroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding? Aliment Pharmacol Ther 2005 Aug 1; 22(3): 175–81PubMedCrossRef
58.
Kurdyak PA, Juurlink DN, Kopp A, et al. Antidepressants, warfarin, and the risk of hemorrhage. J Clin Psychopharmacol 2005 Dec; 25(6): 561–4PubMedCrossRef
59.
Dell’Agnello G, Ceravolo R, Nuti A, et al. SSRIs do not worsen Parkinson’s disease: evidence from an open-label, prospective study. Clin Neuropharmacol 2001 Jul–Aug; 24(4): 221–7PubMedCrossRef
60.
Weintraub D, Morales KH, Moberg PJ, et al. Antidepressant studies in Parkinson’s disease: a review and meta-analysis. Mov Disord 2005 Sep; 20(9): 1161–9PubMedCrossRef
61.
Murphy Jr GM, Hollander SB, Rodrigues HE, et al. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 2004 Nov; 61(11): 1163–9PubMedCrossRef
62.
Lenze EJ, Mulsant BH, Shear MK, et al. Efficacy and tolerability of citalopram in the treatment of late-life anxiety disorders: results from an 8-week randomized, placebo-controlled trial. Am J Psychiatry 2005 Jan; 162(1): 146–50PubMedCrossRef
63.
Ensrud KE, Blackwell TL, Ancoli-Israel S, et al. Use of selective serotonin reuptake inhibitors and sleep disturbances in community-dwelling older women. J Am Geriatr Soc 2006 Oct; 54(10): 1508–15PubMedCrossRef
64.
Murphy Jr GM, Kremer C, Rodrigues HE, et al. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003 Oct; 160(10): 1830–5PubMedCrossRef
65.
Schillevoort I, van Puijenbroek EP, de Boer A, et al. Extrapyramidal syndromes associated with selective serotonin reuptake inhibitors: a case-control study using spontaneous reports. Int Clin Psychopharmacol 2002 Mar; 17(2): 75–9PubMedCrossRef
66.
van de Vijver DAMC, Roos RAC, Jansen PAF, et al. Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa. Br J Clin Pharmacol 2002 Aug; 54(2): 168–70PubMedCrossRef
67.
Caley CF, Friedman JH. Does fluoxetine exacerbate Parkinson’s disease? J Clin Psychiatry 1992 Aug; 53(8): 278–82PubMed
68.
Tesei S, Antonini A, Canesi M, et al. Tolerability of paroxetine in Parkinson’s disease: a prospective study. Mov Disord 2000 Sep; 15(5): 986–9PubMedCrossRef
69.
Ceravolo R, Nuti A, Piccinni A, et al. Paroxetine in Parkinson’s disease: effects on motor and depressive symptoms. Neurology 2000 Oct 24; 55(8): 1216–8PubMedCrossRef
70.
Bonvento G, MacKenzie ET, Edvinsson L. Serotonergic innervation of the cerebral vasculature: relevance to migraine and ischaemia. Brain Res Brain Res Rev 1991 Sep–Dec; 16(3): 257–63PubMedCrossRef
71.
Muhonen MG, Robertson SC, Gerdes JS, et al. Effects of serotonin on cerebral circulation after middle cerebral artery occlusion. J Neurosurg 1997 Aug; 87(2): 301–6PubMedCrossRef
72.
Ramasubbu R. Cerebrovascular effects of selective serotonin reuptake inhibitors: a systematic review. J Clin Psychiatry 2004 Dec; 65(12): 1642–53PubMedCrossRef
73.
Singhal AB, Caviness VS, Begleiter AF, et al. Cerebral vasoconstriction and stroke after use of serotonergic drugs. Neurology 2002 Jan 8; 58(1): 130–3PubMedCrossRef
74.
Ramasubbu R, Patten SB. Effect of depression on stroke morbidity and mortality. Can J Psychiatry 2003 May; 48(4): 250–7PubMed
75.
Spigset O. Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system. Drug Saf 1999 Mar; 20(3): 277–87PubMedCrossRef
76.
Beasley Jr CM, Koke SC, Nilsson ME, et al. Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis. Clin Ther 2000 Nov; 22(11): 1319–30PubMedCrossRef
77.
Preda A, MacLean RW, Mazure CM, et al. Antidepressant- associated mania and psychosis resulting in psychiatric admissions. J Clin Psychiatry 2001 Jan; 62(1): 30–3PubMedCrossRef
78.
Cassano GB, Puca F, Scapicchio PL, et al. Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients. J Clin Psychiatry 2002 May; 63(5): 396–402PubMedCrossRef
79.
Burrows AB, Salzman C, Satlin A, et al. A randomized, placebo-controlled trial of paroxetine in nursing home residents with non-major depression. Depress Anxiety 2002; 15(3): 102–10PubMedCrossRef
80.
Joss JD, Burton RM, Keller CA. Memory loss in a patient treated with fluoxetine. Ann Pharmacother 2003 Dec; 37(12): 1800–3PubMedCrossRef
81.
Mowla A, Mosavinasab M, Pani A. Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment? A double-blind, placebo-controlled, clinical trial. J Clin Psychopharmacol 2007 Feb; 27(1): 67–70PubMedCrossRef
82.
Petitpain N, Gambier N, Gillet P, et al. Dysphonia induced by selective serotonin reuptake inhibitors [letter]. South Med J 2005 Aug; 98(8): 843PubMedCrossRef
83.
Cipriani A, Barbui C, Geddes JR. Suicide, depression, and antidepressants. BMJ 2005 Feb 19; 330(7488): 373–4PubMedCrossRef
84.
Fergusson D, Doucette S, Glass KC, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials [published erratum appears in BMJ 2005 Mar 19; 330 (7492): 653]. BMJ 2005 Feb 19; 330(7488): 396–402PubMedCrossRef
85.
Didham RC, McConnell DW, Blair HJ, et al. Suicide and self-harm following prescription of SSRIs and other antidepressants: confounding by indication. Br J Clin Pharmacol 2005 Nov; 60(5): 519–25PubMedCrossRef
86.
Friedman R, Leon A. Expanding the black box: depression, antidepressants, and the risk of suicide. N Engl J Med 2007; 356: 2343–6PubMedCrossRef
87.
Koski A, Vuori E, Ojanpera I. Newer antidepressants: evaluation of fatal toxicity index and interaction with alcohol based on Finnish postmortem data. Int J Legal Med 2005 Nov; 119(6): 344–8PubMedCrossRef
88.
89.
Isacsson G, Rich CL. Antidepressant drug use and suicide prevention. Int Rev Psychiatry 2005; 1(17): 153–62CrossRef
90.
Hall W, Mant A, Mitchell P, et al. Association between antidepressant prescribing and suicide in Australia; 1991–2000: trend analysis. BMJ 2003; 326(7397): 1008–112PubMedCrossRef
91.
Draper B. Antidepressant prescribing and suicide: associations attribute possible causality inappropriately [letter]. BMJ 2003; 327(7409): 288PubMedCrossRef
92.
Juurlink DN, Mamdani MM, Kopp A, et al. The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Am J Psychiatry 2006 May; 163(5): 813–21PubMedCrossRef
93.
Ensrud KE, Blackwell T, Mangione CM, et al. Central nervous system active medications and risk for fractures in older women. Arch Intern Med 2002 Apr 28; 163(8): 949–57CrossRef
94.
Arfken CL, Wilson JG, Aronson SM. Retrospective review of selective serotonin reuptake inhibitors and falling in older nursing home residents. Int Psychogeriatr 2001 Mar; 13(1): 85–91PubMedCrossRef
95.
Kallin K, Gustafson Y, Sandman P-O, et al. Drugs and falls in older people in geriatric care settings. Aging Clin Exp Res 2004 Aug; 16(4): 270–6PubMed
96.
Liu B, Anderson G, Mittmann N, et al. Use of selective serotonin-reuptake inhibitors of tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 1998 May 2; 351(9112): 1303–7PubMedCrossRef
97.
Hubbard R, Farrington P, Smith C, et al. Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture. Am J Epidemiol 2003 Jul 1; 158(1): 77–84PubMedCrossRef
98.
French DD, Campbell R, Spehar A, et al. Outpatient medications and hip fractures in the US: a national veterans study. Drugs Aging 2005; 22(10): 877–85PubMedCrossRef
99.
Pacher P, Ungvari Z. Selective serotonin-reuptake inhibitor antidepressants increase the risk of falls and hip fractures in elderly people by inhibiting cardiovascular ion channels. Med Hypotheses 2001 Oct; 57(4): 469–71PubMedCrossRef
100.
Rodriguez de la Torre B, Dreher J, Malevany I, et al. Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonic reuptake inhibitors in depressed patients. Ther Drug Monit 2001 Aug; 23(4): 435–40PubMedCrossRef
101.
Cherin P, Colvez A, Deville de Periere G, et al. Risk of syncope in the elderly and consumption of drugs: a case-control study. J Clin Epidemiol 1997 Mar; 50(3): 313–20PubMedCrossRef
102.
Le Couteur DG, Fisher AA, Davis MW, et al. Postprandial systolic blood pressure responses of older people in residential care: association with risk of falling. Gerontology 2003 Jul–Aug; 49(4): 260–4PubMedCrossRef
103.
Jensen J, Lundin-Olsson L, Nyberg L, et al. Falls among frail older people in residential care. Scand J Public Health 2002; 30(1): 54–61PubMed
104.
Mamo DC, Pollock BG, Mulsant B, et al. Effects of nortriptyline and paroxetine on postural sway in depressed elderly patients. Am J Geriatr Psychiatry 2002 Mar–Apr; 10(2): 199–205PubMed
105.
Jacob S, Spinler SA. Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults. Ann Pharmacother 2006 Sep; 40(9): 1618–22PubMedCrossRef
106.
Kirby D, Ames D. Hyponatraemia and selective serotonin reuptake inhibitors in elderly patients. Int J Geriatr Psychiatry 2001 May; 16(5): 484–93PubMedCrossRef
107.
Stedman CAM, Begg EJ, Kennedy MA, et al. Cytochrome P450 2D6 genotype does not predict SSRI (fluoxetine or paroxetine) induced hyponatraemia. Hum Psychopharmacol 2002 Jun; 17(4): 187–90PubMedCrossRef
108.
Odeh M, Seligmann H, Oliven A. Severe life-threatening hyponatremia during paroxetine therapy. J Clin Pharmacol 1999 Dec; 39(12): 1290–1PubMedCrossRef
109.
Degner D, Grohmann R, Kropp S, et al. Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry 2004 Mar; 37Suppl. 1: S39–45PubMed
110.
Kirchner V, Silver LE, Kelly CA. Selective serotonin reuptake inhibitors and hyponatraemia: review and proposed mechanisms in the elderly. J Psychopharmacol 1998; 12(4): 396–400PubMedCrossRef
111.
Kirby D, Harrigan S, Ames D. Hyponatraemia in elderly psychiatric patients treated with selective serotonin reuptake inhibitors and venlafaxine: a retrospective controlled study in an inpatient unit. Int J Geriatr Psychiatry 2002 Mar; 17(3): 231–7PubMedCrossRef
112.
Arinzon ZH, Lehman YA, Fidelman ZG, et al. Delayed recurrent SIADH associated with SSRIs. Ann Pharmacother 2002 Jul–Aug; 36(7–8): 1175–7PubMedCrossRef
113.
Pollak PT, Mukherjee SD, Fraser AD. Sertraline-induced hypoglycemia. Ann Pharmacother 2001 Nov; 35(11): 1371–4PubMedCrossRef
114.
Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine (Baltimore) 2005 Nov; 84(6): 377–85CrossRef
115.
Bonin B, Vandel P, Sechter D, et al. Paroxetine and galactorrhea. Pharmacopsychiatry 1997 Jul; 30(4): 133–4PubMedCrossRef
116.
Gonzalez E, Minguez L, Sanguino RM. Galactorrhea after paroxetine treatment [letter]. Pharmacopsychiatry 2000 May; 33(3): 118PubMedCrossRef
117.
Davenport E, Velamoor R. A case of paroxetine-induced galactorrhea. Can J Psychiatry 2002 Nov; 47(9): 890–1PubMed
118.
Brucculeri M, Kaplan J, Lande L. Reversal of citalopram- induced junctional bradycardia with intravenous sodium bicarbonate. Pharmacotherapy 2005 Jan; 25(1): 119–22PubMedCrossRef
119.
Isbister GK, Bowe SJ, Dawson A, et al. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol 2004; 42(3): 277–85PubMedCrossRef
120.
Tata LJ, West J, Smith C, et al. General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction. Heart 2005 Apr; 91(4): 465–71PubMedCrossRef
121.
Xiong GL, Jiang W, Clare R, et al. Prognosis of patients taking selective serotonin reuptake inhibitors before coronary artery bypass grafting. Am J Cardiol 2006 Jul 1; 98(1): 42–7PubMedCrossRef
122.
Schlienger RG, Fischer LM, Jick H, et al. Current use of selective serotonin reuptake inhibitors and risk of acute myocardial infarction. Drug Saf 2004; 27(14): 1157–65PubMedCrossRef
123.
Serebruany VL, Glassman AH, Malinin AI, et al. Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin. Eur J Heart Fail 2003 Aug; 5(4): 517–21PubMedCrossRef
124.
Sauer WH, Berlin JA, Kimmel SE. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation 2003 Jul 8; 108(1): 32–6PubMedCrossRef
125.
Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation 2001 Oct 16; 104(16): 1894–8PubMedCrossRef
126.
MacDonald TM, McMahon AD, Reid IC, et al. Antidepressant drug use in primary care: a record linkage study in Tayside, Scotland. BMJ 1996 Oct 5; 313(7061): 860–1PubMedCrossRef
127.
Meier CR, Schlienger RG, Jick H. Use of selective serotonin reuptake inhibitors and risk of developing first-time acute myocardial infarction. Br J Clin Pharmacol 2001 Aug; 52(2): 179–84PubMedCrossRef
128.
Monster TBM, Johnsen SP, Olsen ML, et al. Antidepressants and risk of first-time hospitalization for myocardial infarction: a population-based case-control study. Am J Med 2004 Nov 15; 117(10): 732–7PubMedCrossRef
129.
Votolato NA, Stern S, Caputo RM. Serotonergic antidepressants and urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2000 Dec; 11(6): 386–8PubMedCrossRef
130.
Movig KLL, Leufkens HGM, Belitser SV, et al. Selective serotonin reuptake inhibitor-induced urinary incontinence. Pharmacoepidemiol Drug Saf 2002 Jun; 11(4): 271–9PubMedCrossRef
131.
Asplund R, Johansson S, Henriksson S, et al. Nocturia, depression and antidepressant medication. BJU Int 2005 Apr; 95(6): 820–3PubMedCrossRef
132.
Steingart A, Cotterchio M, Kreiger N, et al. Antidepressant medication use and breast cancer risk: a case-control study. Int J Epidemiol 2003 Dec; 32(6): 961–6PubMedCrossRef
133.
Cotterchio M, Kreiger N, Darlington G, et al. Antidepressant medication use and breast cancer risk. Am J Epidemiol 2000 May 15; 151(10): 951–7PubMedCrossRef
134.
Kelly JP, Rosenberg L, Palmer JR, et al. Risk of breast cancer according to use of antidepressants, phenothiazines, and antihistamines. Am J Epidemiol 1999 Oct 15; 150(8): 861–8PubMedCrossRef
135.
Chien C, Li CI, Heckbert SR, et al. Antidepressant use and breast cancer risk. Breast Cancer Res Treat 2006 Jan; 95(2): 131–40PubMedCrossRef
136.
Wang PS, Walker AM, Tsuang MT, et al. Antidepressant use and the risk of breast cancer: a non-association. J Clin Epidemiol 2001 Jul; 54(7): 728–34PubMedCrossRef
137.
Barkla DH, Tutton PJ. Influence of histamine and serotonin antagonists on the growth of xenografted human colorectal tumors. J Natl Cancer Inst 1981 Dec; 67(6): 1207–11PubMed
138.
Xu W, Tamim H, Shapiro S, et al. Use of antidepressants and risk of colorectal cancer: a nested case-control study. Lancet Oncol 2006 Apr; 7(4): 301–8PubMedCrossRef
139.
Mercke Y, Sheng H, Khan T, et al. Hair loss in psychopharmacology. Ann Clin Psychiatry 2000 Mar; 12(1): 35–42PubMed
140.
Hedenmalm K, Sundstrom A, Spigset O. Alopecia associated with treatment with selective serotonin reuptake inhibitors (SSRIs). Pharmacoepidemiol Drug Saf 2006 Oct; 15(10): 719–25PubMedCrossRef
141.
Gulec AT, Tanriverdi N, Duru C, et al. The role of psychological factors in alopecia areata and the impact of the disease on the quality of life. Int J Dermatol 2004 May; 43(5): 352–6PubMedCrossRef
142.
143.
Bertilsson L, Dahl M-L, Dalen P, et al. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002 Feb; 53(2): 111–22PubMedCrossRef
144.
Feng Y, Pollock BG, Ferrell RE, et al. Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling. Br J Clin Pharmacol 2006 May; 61(5): 558–69PubMedCrossRef
145.
Kirchheiner J, Brosen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages [erratum appears in Acta Psychiatr Scand 2001 Dec; 104 (6): 475]. Acta Psychiatr Scand 2001 Sep; 104(3): 173–92PubMedCrossRef
146.
Wedlund PJ, de Leon J. Cytochrome P450 2D6 and antidepressant toxicity and response: what is the evidence? Clin Pharmacol Ther 2004 May; 75(5): 373–5PubMedCrossRef
147.
Rau T, Wohlleben G, Wuttke H, et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants: a pilot study. Clin Pharmacol Ther 2004 May; 75(5): 386–93PubMedCrossRef
148.
Zourkova A, Hadasova E. Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurrence of adverse effects. Gen Physiol Biophys 2003 Mar; 22(1): 103–13PubMed
149.
Roberts RL, Mulder RT, Joyce PR, et al. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline [see comment]. Hum Psychopharmacol 2004 Jan; 19(1): 17–23PubMedCrossRef
150.
Solai LK, Pollock BG, Mulsant BH, et al. Effect of nortriptyline and paroxetine on CYP2D6 activity in depressed elderly patients. J Clin Psychopharmacol 2002 Oct; 22(5): 481–6PubMedCrossRef
151.
Pollock BG, Ferrell RE, Mulsant BH, et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000 Nov; 23(5): 587–90PubMedCrossRef
152.
Perlis RH, Mischoulon D, Smoller JW, et al. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatry 2003 Nov 1; 54(9): 879–83PubMedCrossRef
Metadata
Title
Tolerability of Selective Serotonin Reuptake Inhibitors
Issues Relevant to the Elderly
Authors
Dr Brian Draper
Karen Berman
Publication date
01-06-2008
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 6/2008
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200825060-00004

Other articles of this Issue 6/2008

Drugs & Aging 6/2008 Go to the issue

Original Research Article

Glutathione S-Transferase P1 Ile105Val Polymorphism is Associated with Haematological Toxicity in Elderly Rectal Cancer Patients Receiving Preoperative Chemoradiotherapy

Original Research Article

Cost Effectiveness of Withdrawal of Fall-Risk-Increasing Drugs in Geriatric Outpatients

Current Opinion

Compliance with Medication in Nursing Homes for Older People

Therapy In Practice

Management of Acute Renal Failure in the Elderly Patient

Review Article

Monitored Anaesthesia Care in the Elderly
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits